Heterogeneity within the PF-EPN-B ependymoma subgroup by Cavalli, Florence M. G. et al.
Vol.:(0123456789) 
Acta Neuropathologica (2018) 136:227–237 
https://doi.org/10.1007/s00401-018-1888-x
ORIGINAL PAPER
Heterogeneity within the PF‑EPN‑B ependymoma subgroup
Florence M. G. Cavalli1 · Jens‑Martin Hübner2,3,4 · Tanvi Sharma2,3,4 · Betty Luu1 · Martin Sill3 · Michal Zapotocky5 · 
Stephen C. Mack6 · Hendrik Witt2,3,41 · Tong Lin7 · David J. H. Shih8 · Ben Ho5 · Mariarita Santi9 · Lyndsey Emery10 · 
Juliette Hukin11 · Christopher Dunham12 · Roger E. McLendon13 · Eric S. Lipp13 · Sridharan Gururangan14 · 
Andrew Grossbach15 · Pim French16 · Johan M. Kros16 · Marie‑Lise C. van Veelen16 · Amulya A. Nageswara Rao17 · 
Caterina Giannini18 · Sarah Leary19 · Shin Jung20 · Claudia C. Faria21 · Jaume Mora22 · Ulrich Schüller23 · 
Marta M. Alonso24 · Jennifer A. Chan25 · Almos Klekner26 · Lola B. Chambless27 · Eugene I. Hwang28 · 
Maura Massimino29 · Charles G. Eberhart30 · Matthias A. Karajannis31 · Benjamin Lu32 · Linda M. Liau33 · 
Massimo Zollo34 · Veronica Ferrucci34 · Carlos Carlotti35 · Daniela P. C. Tirapelli35 · Uri Tabori5 · Eric Bouffet5 · 
Marina Ryzhova36 · David W. Ellison37 · Thomas E. Merchant38 · Mark R. Gilbert39 · Terri S. Armstrong39 · 
Andrey Korshunov40 · Stefan M. Pfister2,3,41 · Michael D. Taylor1,42 · Kenneth Aldape43 · Kristian W. Pajtler2,3,41 · 
Marcel Kool2,3 · Vijay Ramaswamy1,5 
Received: 13 June 2018 / Revised: 11 July 2018 / Accepted: 11 July 2018 / Published online: 17 July 2018 
© Springer-Verlag GmbH Germany, part of Springer Nature 2018
Abstract
Posterior fossa ependymoma comprise three distinct molecular variants, termed PF-EPN-A (PFA), PF-EPN-B (PFB), and 
PF-EPN-SE (subependymoma). Clinically, they are very disparate and PFB tumors are currently being considered for a trial 
of radiation avoidance. However, to move forward, unraveling the heterogeneity within PFB would be highly desirable. To 
discern the molecular heterogeneity within PFB, we performed an integrated analysis consisting of DNA methylation profil-
ing, copy-number profiling, gene expression profiling, and clinical correlation across a cohort of 212 primary posterior fossa 
PFB tumors. Unsupervised spectral clustering and t-SNE analysis of genome-wide methylation data revealed five distinct 
subtypes of PFB tumors, termed PFB1-5, with distinct demographics, copy-number alterations, and gene expression profiles. 
All PFB subtypes were distinct from PFA and posterior fossa subependymomas. Of the five subtypes, PFB4 and PFB5 are 
more discrete, consisting of younger and older patients, respectively, with a strong female-gender enrichment in PFB5 (age: 
p = 0.011, gender: p = 0.04). Broad copy-number aberrations were common; however, many events such as chromosome 2 
loss, 5 gain, and 17 loss were enriched in specific subtypes and 1q gain was enriched in PFB1. Late relapses were common 
across all five subtypes, but deaths were uncommon and present in only two subtypes (PFB1 and PFB3). Unlike the case in 
PFA ependymoma, 1q gain was not a robust marker of poor progression-free survival; however, chromosome 13q loss may 
represent a novel marker for risk stratification across the spectrum of PFB subtypes. Similar to PFA ependymoma, there exists 
a significant intertumoral heterogeneity within PFB, with distinct molecular subtypes identified. Even when accounting for 
this heterogeneity, extent of resection remains the strongest predictor of poor outcome. However, this biological heterogene-
ity must be accounted for in future preclinical modeling and personalized therapies.
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Introduction
Genomics has significantly advanced our knowledge of the 
biology of posterior fossa ependymoma [9–11, 14, 20, 23, 
24, 26]. Posterior fossa ependymoma comprise three dis-
tinct molecular subgroups, defined by gene expression and 
genome-wide DNA methylation, and they display highly 
disparate demographics, cytogenetics, and outcomes [6, 
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11, 12, 14–16, 26]. PFA (PF-EPN-A) ependymomas arise 
in younger patients, primarily infants, and have generally a 
bland genome and a poor outcome. In contrast, PFB (PF-
EPN-B) ependymomas occur in older children and adults, 
harbor multiple broad cytogenetic aberrations, and generally 
have a favorable outcome. The third molecular subgroup 
comprises mostly grade I subependymomas (PF-SE), which 
occur almost exclusively in adults only and have a good out-
come, as well [14]. Currently, the standard of care for all 
posterior fossa ependymoma in patients under 18 is maximal 
safe surgical resection followed by conformal radiation to 
the tumor bed; however, in adults, adjuvant postoperative 
radiation is variable resulting in a subset of patients who are 
treated with surgery only [19].
Recently, we demonstrated that there are profound clini-
cal differences and responses to therapy between PFA and 
PFB [14, 15, 26]. PFA have a poor outcome overall, with an 
even worse outcome when sub-totally resected. PFB have 
an excellent outcome overall, where a significant propor-
tion of patients can be cured with a gross total resection 
alone. Therefore, patients with PFB ependymoma, particu-
larly children are excellent candidates for radiation sparing 
strategies, where carefully controlled studies are being con-
templated of observation alone in the setting of gross total 
resection. Gain of 1q has been proposed as a marker of poor 
prognosis in PFA ependymoma; however, its role in PFB is 
unclear [1, 4, 7, 8, 17, 25]. We have also recently shown that 
PFA ependymoma is highly heterogeneous entities with two 
major groups with multiple subtypes [13]. Moreover, PFB 
has been assumed to be a homogeneous group; however, it is 
unknown if there exists molecular and/or clinical heteroge-
neity and additional substructure within PFB ependymoma. 
As such, unraveling this heterogeneity will be a crucial 
starting point to the development of personalized thera-
pies within PFB. We assembled the largest cohort to date 
of clinically annotated PFB ependymomas profiled using 
genome-wide DNA methylation arrays to assess molecular 
heterogeneity within the PFB ependymoma subgroup.
Methods
Patient cohort
Two hundred and twelve posterior fossa ependymomas 
were obtained through the GENE consortium (Global 
Ependymoma Network of Excellence), St. Jude’s Children’s 
Research Hospital, the Collaborative Ependymoma Research 
Network, the Burdenko Neurosurgical Institute, and the 
German Cancer Research Center. Both frozen and FFPE 
samples were collected from diagnosis. Samples were all 
collected in accordance with the Hospital for Sick Children 
Research Ethics Board and local institutional research ethics 
boards. All frozen samples were snap frozen and stored at 
− 80 °C. Formalin-fixed paraffin-embedded tissue was col-
lected as scrolls or unstained slides. A subtotal resection 
was defined as more than 5 mm postoperative residual on 
the postoperative MRI.
Genome‑wide DNA methylation profiling
Samples were analyzed on the Illumina Infinium Human-
Methylation450 or the HumanMethylationEPIC beadchips at 
the PM-OICR Translational Genomics Laboratory (Toronto, 
Ontario) or the German Cancer Research Center (Heidel-
berg, Germany) according to the manufacturer’s instructions 
and as previously described [14]. All analysis was con-
ducted in the R Statistical Environment (v3.4.1). Raw data 
files (.idat) generated by the Illumina iScan array scanner 
from both frozen and FFPE derived tissue were loaded and 
preprocessed using the minfi package (v1.22.1). Illumina 
preprocessing was selected to mimic the normalization per-
formed in Illumina Genome Studio. To account for possible 
batch effects due to divergent protocols for fresh frozen and 
FFPE material, a batch adjustment was performed. Batch 
effects were estimated by fitting a linear model to the log2 
transformed intensity values of the methylated and unmeth-
ylated channels. After removing the component due to the 
batch effect, the residuals were backtransformed to inten-
sity scale, and methylation beta values were calculated as 
described in Illumina’s protocols. Subsequently, the follow-
ing filtering criteria were applied: removal of probes target-
ing the X and Y chromosomes, removal of probes containing 
a single-nucleotide polymorphism (dbSNP132 Common) 
within five base pairs of and including the targeted CpG site, 
and probes not mapping uniquely to the human reference 
genome (hg19) allowing for one mismatch. In total, 431069 
probes were kept for analysis. PFB status was determined 
using the Heidelberg brain tumor classifier (https ://www.
molec ularn europ athol ogy.org/mnp) and unsupervised hier-
archical clustering as previously described [2, 14]. Raw and 
processed methylation data have been deposited into GEO 
under the accession number GSE117130.
Gene expression profiling
PFB ependymoma samples, for which gene expression 
profiles generated on the Affymetrix GeneChip Human 
Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, 
USA) at the Microarray Department of the University of 
Amsterdam, The Netherlands, were processed as previ-
ously described (GSE64415) [13, 14]. Briefly, data were 
normalized using the MAS5.0 algorithm, and differentially 
expressed genes between the five subtypes were generated 
within the R2: Genomics Analysis and Visualization Plat-
form comparing one (http://r2.amc.nl). TMEV software 
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was used to generate the heatmap displaying the top ten 
most upregulated genes per subtype [21]. Differentially 
expressed genes (adj. p < 0.05) when comparing one sub-
type versus others were used to performed pathway analy-
sis with g:profiler [18].
Unsupervised t‑SNE analysis
For unsupervised t-Distributed Stochastic Neighbor Embed-
ding (t-SNE) analysis, we selected the 6749 most variably 
methylated probes across the data set (s.d. > 0.25). Pair-
wise sample distances were calculated using 1 minus the 
weighted Pearson correlation coefficient as the distance 
measure. Unweighted correlation coefficients provided simi-
lar results and as such weighted probes were used to reduce 
the noise. Pairwise Pearson correlation was calculated using 
the wtd.cors function of the weights package v.0.85. We 
used the probe standard deviation subtracted by 0.25 as the 
weight, giving more variable probes greater influence. The 
resulting distance matrix was used to perform the t-SNE 
analysis (Rtsne package v.0.13). The following non-default 
parameters were used: θ = 0, is_distance = T, pca = F, 
and max_iter = 2000. Clusters were annotated using the 
DBSCAN algorithm as implemented in the dbscan package 
v.1.1.1. The following non-default parameters were used: 
minPts = 10, eps = 2.4. Subsequently, samples not assigned 
to any cluster were iteratively merged to their nearest cluster.
Spectral clustering
The same weighted distance matrix used for unsupervised 
t-SNE analysis was used to perform spectral clustering. 
Spectral clustering implemented in the SNFtool package 
(v2.2.1) was run on the patient by patient similarity matrix 
to obtain groups corresponding to k = 2–8.
Copy number variation (CNV) analysis
Copy-number segmentation was performed from genome-
wide methylation arrays using the conumee package 
(v0.99.4) in the R statistical environment (v3.3.3) as previ-
ously described [5, 22]. Broad copy-number events were 
determined using visual inspection of copy-number plots 
and significance of the frequency of each broad event was 
tested using the exact binomial test. Each broad event fre-
quency was compared to the background frequency, which 
was determined from a robust regression of the observed 
frequencies with respect to gene content (i.e., number of 
RefSeq genes) across all chromosomes. This approach was 
motivated by GISTIC’s broad event analysis [3].
Statistical analysis
Progression-free survival and overall survival were ana-
lyzed by the Kaplan–Meier method, and p values reported 
using the log-rank test. Associations between covariates 
and risk groups were tested by the Fisher’s exact test. Uni-
variable and multivariable cox proportional hazard regres-
sion was used to estimate hazard ratios including 95% con-
fidence intervals. All statistical analyses were performed 
in the R statistical environment (v3.4.1), using R packages 
survival (v2.41-3), and ggplot2 (v2.2.1).
Results
DNA methylation profiling identifies five distinct 
subtypes of PFB ependymoma
Genome-wide methylation profiling was available on 212 
primary posterior fossa ependymomas (76 frozen and 136 
formalin-fixed paraffin-embedded samples) previously 
assigned to the PFB subgroup using either the Illumina 
HumanMethylation450 (n = 180) or HumanMethylationE-
PIC arrays (n = 32) and the Heidelberg brain tumor classi-
fier (https ://www.molec ularn europ athol ogy.org/mnp) [2].
To discern the extent of heterogeneity within the PFB 
subgroup, we applied unsupervised clustering using the 
most variably methylated probes with a standard devia-
tion over 0.25. A distance matrix was constructed using 1 
minus the weighted Pearson correlation, and both t-SNE 
analysis and spectral clustering were applied to the result-
ing distance matrix (Fig. 1a, b). Using the t-SNE analy-
sis performing 2000 iterations, five distinct clusters were 
identified which we term subtypes. Spectral clustering was 
also applied for k = 2 to k = 8, confirming the optimal clus-
ters at k = 5 (Fig. 1b, Supplemental Fig. 1). The subtypes 
obtained by t-SNE and the spectral clustering were also 
largely identical when the t-SNE analysis is compared to 
spectral clustering at k = 5 (Supplemental Fig. 2A). No 
major differences in overall methylation levels at probes 
near the promoter were identified across the five subtypes 
(Supplemental Fig. 2B). In four instances, paired samples 
from diagnosis and relapse were available, and we did not 
observe any switching of subtype at recurrence (1 PFB1, 
2 PFB2, and 1 PFB3).
To determine if any of the PFB subtypes were closer to 
PF-SE subependymoma, particularly the ones with older 
age, we clustered the 212 PFBs with 34 posterior fossa sub-
ependymomas (PF-EPN-SP) and 220 PFAs. The five PFB 
subtypes clustered together, without any overlap with PF-SE 
subependymomas or PFAs, suggesting that the heterogeneity 
within PFB is distinct from the other two groups (Fig. 1c).
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Differential gene expression across PFB subtypes
Array-based gene expression analyses of the five PFB sub-
types (n = 25) reveal the top upregulated genes per subtypes 
(Fig. 1d), Differential expression analysis identifies in total 
693 genes as significantly differentially expressed (adj. 
p < 0.05) between one versus the other four subtypes. Simi-
lar to the methylation-based clustering, PFB4 and PFB5 had 
significantly more differentially expressed genes compared 
to PFB1, 2, and 3 which exhibited fewer differences. Subsets 
of these genes, which included transcription factors, devel-
opmental patterning pathways, and potential drug targets, 
showed upregulated expression within the five subtypes. 
Gene-ranked pathway enrichment analysis of subtype-spe-
cific genes indicated several general and specific develop-
mental processes and developmental patterning pathways 
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Fig. 1  Clustering of PFB reveals five distinct subtypes. a t-SNE plot 
showing the relative distribution of the five subtypes. b Heatmap 
obtained from spectral clustering (SpC), whereby yellow represents 
more similar samples and red represents disparate ones. Color bars at 
the top indicate the t-SNE cluster at k = 5 and the spectral clustering 
clusters (SpC) at k = 5; c t-SNE plot showing PFB clustered concomi-
tantly with PF-SE and PFA. d Heatmap representing the expression 
levels of the ten most differentially expressed genes per subtype. Each 
column represents one sample, and each lane represents one gene. 
Gene expression levels are represented by a color scale as indicated
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identified as deregulated processes, specifically within PFB4 
and PFB5 (Supplemental Fig. 3) [18].
Demographic differences across PFB subtypes
Annotation of demographics of the five subtypes reveals sig-
nificant age differences between the five subtypes, specifi-
cally, an enrichment of younger patients in PFB4 (median 
15 years, IQR 10.1–23.5 years) and enrichment of older 
patients in PFB5 (median 40.6, IQR 28.5–50 years, Fig. 2a 
p = 0.011). PFB1, PFB2, and PFB3 had similar median 
age at diagnosis (PFB1 25.9 years, IQR 13.4–42 years; 
PFB2: median 26 years, IQR 17–41 years; PFB3: median 
29.1 years, IQR 13.2–41 years, Fig. 2a). Moreover, there 
are significant gender differences, wherein PFB2 and PFB4 
have a high male bias, whereas PFB3 and PFB5 have a high 
female patient bias (Fig. 2b, p = 0.04).
PFB subtype‑specific chromosomal aberrations
We generated genome-wide DNA copy-number profiles, 
using the combined intensity of the methylated and unmeth-
ylated probes as previously described [5]. Many samples 
displayed aneuploidy without any recurrent amplifications 
or deletions, consistent with the previous descriptions of 
PFB ependymoma [26]. Moreover, the overall patterns of 
broad copy-number changes were similar to the previous 
reports, including enrichment of 1q gain (12%), monosomy 
6 (61.3%), monosomy 10 (38.7%), monosomy 17 (33.5%), 
trisomy 5 (31.1%), trisomy 8 (23.5%), trisomy 18 (51.9%), 
and 22q loss (48.1%) [14]. However, when we repeated this 
analysis across the PFB subtypes, we observed several sub-
type-specific aberrations like monosomy 2 in PFB2 (PFB1 
17/75, PFB2 18/36, PFB3 10/54, PFB4 4/30, PFB5 1/17, 
p = 0.0014), monosomy 3 in PFB1 (PFB1 38/75, PFB2 
5/36, PFB3 11/54, PFB4 4/30, PFB5 2/17, p = 3.8 × 10−5), 
monosomy 6 in PFB1,2,3 (PFB1 51/75, PFB2 26/36, PFB3 
41/54, PFB4 8/30, PFB5 4/17, p = 1.2 × 10−6), monosomy 8 
in PFB3 (PFB1 1/75, PFB2 5/36, PFB3 25/54, PFB4 2/30, 
PFB5 1/17, p = 1.3 × 10−11), gain of chromosome 11 in PFB4 
(PFB1 17/75, PFB2 13/36, PFB3 14/54, PFB4 21/30, PFB5 
0/17, p = 4.4 × 10−6), and enrichment of 1q gain (PFB1 
19/75, PFB2 5/36, PFB3 1/54, PFB4 0/30, PFB5 1/17, 
p = 1.6 × 10−4) and monosomy 17 (PFB1 44/75, PFB2 10/36, 
PFB3 9/54, PFB4 5/30, PFB5 3/17, p = 1.6 × 10−6) within 
PFB1 (Fig. 3a, b). Copy-number solutions for k = 3 and 4 
Fig. 2  Clinical characteristics 
across PFB subtypes. a Boxplot 
of age at diagnosis across PFB 
subtypes. b Frequency of male 
and female gender within the 
five subtypes. p values for age 
determined using the Kruskal–
Wallis test and frequency of 
gender using the Fisher’s exact 
test
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suggested that PFB1, 2, and 3 were more similar groups 
overall, but, at k = 5, certain broad events were further 
enriched, like monosomy 2 in PFB2, monosomy 8 in PFB3, 
monosomy 3 in PFB1, and gain of 1q in PFB1 (Supplemen-
tal Fig. 3). T-SNE analysis and NMF clustering of broad 
copy-number aberrations could not recapitulate any of the 
observed subtypes (Supplemental Fig. 4).
Extent of surgical resection is the strongest 
predictor of progression‑free survival across PFB 
ependymoma
Survival across the five PFB groups was determined using 
a Kaplan–Meier survival analysis, and no significant differ-
ence in overall or progression-free survival was observed 
Fig. 3  Arm-level cytogenetic 
events across PFB subtypes. 
a Frequency and significance 
of arm-level gains and losses 
across the five PFB subtypes. 
Darker bars show significant 
arm-level events (q value ≤ 0.1, 
Chi-squared test). b Frequency 
and significance of whole 
chromosome gain and losses 
across the five PFB subtypes. 
Darker bars show significant 
arm-level events (q value ≤ 0.1, 
Chi-squared test)
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between the five subtypes (Supplemental Fig. 5A, B). Pro-
gression-free survival was available on 137 cases, and pro-
gression events were evenly distributed across the five sub-
types. Late relapses were common in this cohort, whereby 
13 of the 36 relapses occurred after 5 years and five relapses 
even after 10 years, highlighting the importance of long-
term follow-up in this group. Late relapses were evenly 
distributed across the five subtypes. Sixteen deaths were 
observed in the cohort, nine events in PFB1, and five events 
in PFB3, with one death in each of PFB2 and PFB4, and no 
deaths observed in PFB5.
The rates of incomplete resection and upfront adjuvant 
radiation were not significantly different across the five 
subtypes (Supplemental Fig. 6C, D). Consistent with our 
previous observations, in this cohort overall, a subtotal 
resection portended to a worse progression-free survival in 
a univariable analysis (STR: HR 3.01 95% CI 1.51–5.98 
p = 1.7 × 10−3). Interestingly in this cohort, no upfront radia-
tion and 1q gain were not significant predictors of poor out-
come in a univariable analysis, although both have high haz-
ard ratios, suggesting that they may have a trend to a worse 
outcome (no upfront radiation: HR 1.76 95% CI 0.83–3.75 
p = 0.15; 1q gain: 1.84 95% CI 0.76–4.48 p = 0.18) (Sup-
plemental Table 2).
To discern if other copy-number abnormalities confer 
any prognostic relevance, an exploratory univariable anal-
ysis was undertaken, whereby survival was assessed across 
all copy-number aberrations with at least a 10% incidence. 
Surprisingly, loss of 13q was significant in a univariable 
analysis (Fig. 4, log-rank p = 0.01); a univariable analysis 
of 13q loss compared to both balanced 13q and 13q gain 
confirmed a significant effect size (HR 2.66, 95% CI 
1.262–5.591, p = 0.01). A multivariable analysis was then 
undertaken incorporating 13q and extent of resection, and 
the prognostic value of 13q loss remains significant (HR 
2.73, 95% CI 1.18–5.32 p = 0.017). To further determine 
the relationship between 13q loss and extent of resec-
tion can potentially predict progression-free survival, a 
Kaplan–Meier analysis was performed comparing 13q bal-
anced/gain versus 13q loss stratified by extent of resection, 
which suggests that subtotal resected 13q loss tumors may 
represent a novel high-risk group of PFB ependymoma. 
Loss of 13q was not significant in predicting overall sur-
vival (HR 0.92, 95% CI 0.20–4.20, p = 0.92).
To determine if extent of surgical resection and chromo-
some 13q loss remained prognostic when correcting for 
PFB subtypes, age, gender, 1q gain, and upfront radiation, 
a multivariable analysis of progression-free survival was 
performed (Table 1). Both an incomplete resection and 13q 
loss remained significant, when correcting for co-variants. 
Interestingly, upfront radiation and 1q gain were margin-
ally significant in the multivariable model; however, a sig-
nificant interaction factor could not be discerned between 
a subtotal resection, upfront radiation, and 1q gain. Only 
an incomplete resection was a risk factor for worse overall 
survival (Table 1). Overall outcome was excellent across 
the whole cohort with only 16 deaths across 142 patients, 
and none of the variables above were predictive of death, 
although longer follow-up is likely required.
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Fig. 4  Progression-free survival stratified by a 1q gain and b 13q status. p values determined using the log-rank test
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Discussion
Across the largest cohort of PFB ependymoma assembled 
to date, we show that PFB is comprised of five distinct 
molecular subtypes. These five subtypes display distinct 
demographics and copy-number profiles, suggesting that 
there exists a significant molecular heterogeneity within PFB 
ependymoma. We also show that none of the five subtypes 
of PFB ependymoma overlap with either subependymoma 
or any of the PFA ependymoma subtypes, further strength-
ening the existence of three major molecular subgroups of 
posterior fossa ependymoma.
PFB ependymoma has been considered for de-escalation 
of therapy due to their excellent overall survival [12]. Previ-
ously, we have shown that 50% of gross totally resected PFB 
ependymoma can be cured with surgery alone, suggesting 
that this group could potentially be spared the long-term 
side effects of radiation and/or chemotherapy [15]. Our cur-
rent data suggest that even when correcting for heterogene-
ity within PFB ependymoma, this group can still benefit 
from de-escalation of therapy. However, the observation that 
late relapses are common in PFB highlights that long-term 
follow-up is required for any eventual trial of de-escalation 
of therapy. Overall survival in the cohort was excellent, 
suggesting that successful salvage is possible; however, 
the observation that deaths were enriched in PFB1 and 3 
requires further evaluation in future cohorts.
Several studies over the past 15 years have suggested 1q 
gain to be a marker of poor prognosis across all ependymo-
mas as a whole [7, 8]. However, when 1q is evaluated in a 
subgroup-specific manner, it is only prognostic for progres-
sion-free and overall survival in PFA, with no prognostic 
relevance in the RELA subgroup of supratentorial epend-
ymoma [14]. Indeed, currently, 1q-gained PFA are being 
prioritized urgently for new and novel upfront approaches. 
Our previous work suggested that 1q gain was prognostic for 
progression-free survival but not overall survival within PFB 
[14]. Our current results in a much larger cohort suggest that 
there may be only limited utility to 1q gain as a prognostic 
marker specifically for selection of patients who would ben-
efit from radiation sparing strategies, and this requires fur-
ther evaluation in prospective cohorts. However, the current 
results are consistent with our previous observations that the 
overall survival is not significantly different in PFB patients 
harboring 1q-gained tumors. The relatively high hazard ratio 
for 1q gain suggests that its role as a prognostic marker may 
warrant further evaluation. However, for the next genera-
tion of clinical trials within posterior fossa ependymoma, 
1q should be used for stratification only within PFA, and 
highlights the importance of molecularly informed studies.
We show, for the first time, that identification of chro-
mosome 13q loss may represent a more reliable prognos-
tic marker across PFB ependymoma than 1q gain. Indeed, 
when stratifying chromosome 13q loss by extent of resec-
tion, gross totally resected PFB ependymoma with 13q loss 
appears to still have a poor outcome. The absence of other 
large cohorts of PFB ependymoma precludes its independent 
validation; however, it does warrant further study particu-
larly in the context of ongoing and upcoming prospective 
cooperative group studies.
Most importantly, however, the identification of multi-
ple subtypes of PFB, analogous to recent work across PFA 
ependymoma, shows clearly that there exists a significant 
biological heterogeneity within this group [13]. The cur-
rent cohort is significantly limited by a lack of sufficient 
gene expression data, but the available data support the het-
erogeneity within PFB as determined by methylation pro-
filing. Prospective collection of frozen tissue particularly 
in adults with posterior fossa ependymoma will be crucial 
to determine which specific biological processes underlie 
the observed subtypes. As such, our identification of five 
subtypes provides strong support for the prospective col-
lection of tissue in this group for further next-generation 
integrated analysis. Moreover, the observation that late 
relapses and deaths are not infrequent in this group high-
lights a need to identify and validate actionable pathways. 
Indeed, our identification of multiple subtypes of PFB has 
profound implications for future targeted therapies, as any 
“PFB” specific therapies may be restricted to specific sub-
types. This is especially important in the context of the 
observed subtype-specific copy-number aberrations which 
suggest that PFB tumors do not emerge from a single driv-
ing event. As of today, zero recurrent mutations have been 
found in PFB ependymoma and a clear driver for these 
tumors is still lacking [10]. By focusing on specific PFB 
subtypes and by making use of additional molecular data 
like large gene expression profiling and more comprehensive 
Table 1  Multivariable cox proportional hazards model of survival 
across PFB ependymoma
GTR gross total resection
HR 95% CI p value
Progression-free survival
 Age 0.98 0.96–1.01 0.24
 Male gender 0.70 0.33–1.48 0.35
 Non-GTR 4.48 1.93–9.63 3.8 × 10−4
 Upfront radiation 0.36 0.15–0.85 0.020
Subtype
 PFB2 vs PFB1 0.78 0.25–2.27 0.62
 PFB3 vs PFB1 0.64 0.26–1.86 0.48
 PFB4 vs PFB1 0.56 0.13–2.12 0.37
 PFB5 vs PFB1 0.84 0.14–4.12 0.75
1q gain 2.73 1.01–7.37 0.046
13q loss 3.88 1.54–9.80 0.0041
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next-generation-sequencing enriching for each subtype, 
future studies may be able to elucidate the underlying events 
that ultimately lead to the development of these tumors [10].
Further delineating the biology and prognostic mark-
ers of PFB ependymoma will require extensive collabora-
tion across adult and pediatric centres, as currently adult 
ependymoma is an often-neglected entity, with a paucity of 
frozen tissue available. However, future basic science and 
translational science efforts on PFB should account for the 
heterogeneity within PFB ependymoma in the development 
of more targeted therapeutics.
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